PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Addict Behav. Author manuscript; available in PMC Jul 1, 2012.
Published in final edited form as:
PMCID: PMC3081955
NIHMSID: NIHMS275269
Do smoking reduction interventions promote cessation in smokers not ready to quit?
Taghrid Asfar,a* Jon O. Ebbert,b Robert C. Klesges,ac and George E. Relyead
a Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Mail Stop 735, Memphis, TN, 38105, USA
b Division of Primary Care Internal Medicine, 221 Fourth Avenue SW, Mayo Clinic, Rochester, MN, 55905, USA
c Department of Preventive Medicine, University of Tennessee Heath Science Center, 66 North Pauline Street, Suite 633, Memphis, TN, 38163 USA
d Division of Epidemiology and Biostatistics, School of Public Health, University of Memphis, 3820 DeSoto Avenue, Memphis, TN, 38152 USA
* Corresponding Author: Taghrid Asfar, MD, Department of Epidemiology and Cancer Control, Mail Stop 735, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, taghrid.asfar/at/stjude.org, Phone: + 1 901 595 5502, Fax: + 1 901 495 5845
Background
Limited treatment options exist for smokers who are not ready to make a quit attempt. Smoking reduction may be a viable treatment approach if proven to increase the rates of long-term abstinence from smoking.
Method
A systematic review of randomized, controlled trials that tested smoking-reduction interventions (pharmacological, behavioral, or both combined) among smokers who were not ready to make a quit attempt (immediately or in the next month) was conducted to assess the efficacy of these strategies in promoting future smoking abstinence. The primary outcome was the 7-day point-prevalence smoking abstinence at longest follow-up (≥ 6 months). Ten trials were included; six tested pharmacologic interventions, one evaluated a behavioral intervention, and three evaluated combined interventions.
Results
Pharmacologic (2732 participants; OR 2.33, 95% CI 1.43 to 3.79) and combined (638 participants; OR 2.14, 95% CI: 1.28 to 3.60) smoking-reduction interventions significantly increased long-term abstinence from smoking. Insufficient evidence was available on the efficacy of behavioral smoking-reduction interventions (320 participants; OR 1.49, 95% CI 0.56 to 3.93).
Conclusions
Further research to evaluate the efficacy of smoking reduction should have cessation as an endpoint, focus on clarity and consistency in patient selection, and identify the mechanism through which nicotine replacement therapy assisted smoking reduction in increasing abstinence rates.
Keywords: Smoking reduction, controlled smoking, reduce smoking, NRT assisted smoking reduction, promote abstinence, smokers unwilling/unable to quit smoking
In the United States, 20.6% of adults report that they smoke cigarettes (CDC, 2009). Quitting smoking significantly reduces risk of smoking-related illnesses (USDHHS, 2004). However, 80% of smokers are not ready or willing to quit smoking immediately or during the next month (Velicer, et al., 1995).
The United States Public Health Service’s (USPHS’s) Clinical Practice Guideline (USPHS, 2008) recommends that smokers who are currently unwilling to make a quit attempt be given a brief motivational intervention. However, this assertion is based on limited evidence about the potential benefit of such a strategy (Carpenter, Hughes, & Keely, 2003; Carpenter, Hughes, Solomon, & Callas, 2004), and reports of its efficacy are inconsistent (Burke, Arkowitz, & Menchola, 2003; Dunn, Deroo, & Rivara, 2001; Rubak, Sandbaek, Lauritzen, & Christensen, 2005).
One strategy not mentioned by the USPHS Clinical Practice Guideline is smoking reduction. This strategy aims to engage smokers not ready to make a quit attempt in several behavioral strategies to reduce the number of cigarettes smoked per day (Shiffman, et al., 2002). Smoking reduction has been explored as a route to quitting (Cinciripini, et al., 1995) and as a “harm-reduction” strategy having the goal of decreasing smoking-related morbidity and mortality (Kunze, 2000). However, the value of this approach is controversial for several reasons: (a) uncertainty about its net health benefits (Godtfredsen, Osler, Vestbo, Andersen, & Prescott, 2003; Hatsukami, Hecht, Hennrikus, Joseph, & Pentel, 2003; Pisinger & Godtfredsen, 2007; Tverdal & Bjartveit, 2006); (b) concern that short-term decreases in smoking will not be maintained; and (c) concern that future quit attempts will be undermined (Glasgow, Morray, & Lichtenstein, 1989). Yet, a previous review on smoking reduction (Hughes & Carpenter, 2006) indicates that many smokers are able to reduce their smoking and maintain significant reductions for long periods and that this reduction does not appear to undermine cessation. In addition, smoking reduction may engage a broader population of smokers than traditional smoking-cessation interventions (Glasgow, et al., 2006; Shiffman, et al., 2007).
We conducted a systematic review assessing the efficacy of smoking reduction interventions in promoting future abstinence among cigarette smokers not ready to make a quit attempt immediately or in the next month. Four previous reviews of smoking-reduction interventions for smokers not ready to make a quit attempt have been conducted (Hughes & Carpenter, 2006; Moore, et al., 2009; Stead & Lancaster, 2007; Wang, et al., 2008). One (Hughes & Carpenter, 2006) is a qualitative review that included studies having several different designs (e.g., RCTs, cross-sectional, and prospective studies); we restricted our analysis to only randomized, controlled clinical trials RCTs evaluating interventions to promote smoking reduction as a means of increasing future abstinence. This review and a Cochrane review (Stead & Lancaster, 2007) included one study (Kralikova, Kozak, Rasmussen, Gustavsson, & Le Houezec, 2009) that recruited smokers who were willing to quit smoking and those who were unwilling; we limited our study to trials that recruited only smokers not ready to quit smoking. In addition, most of the previous reviews (Moore, et al., 2009; Stead & Lancaster, 2007; Wang, et al., 2008) include only pharmacological intervention trials (i.e., nicotine replacement therapy [NRT] or bupropion versus placebo), and ours includes three categories of intervention with effect sizes calculated separately: pharmacological, behavioral, and combined. Our review also makes available new evidence (Glasgow, et al., 2009; Joseph, et al., 2008) not included in previous reviews. We sought to determine if smoking reduction facilitates smoking abstinence in individuals who are currently not ready to quit smoking rather than evaluating this method as a way to quit among smokers actively trying to quit (i.e., reduction as a means of gradual cessation) (Lindson, Aveyard, & Hughes, 2010).
We searched MEDLINE, Google Scholar, Embase, CINAHL, PsycINFO, Web of Science citation databases, and the Cochrane Tobacco Addiction Group’s specialized register by using “smoking reduction”, “controlled smoking”, “reduction in cigarettes”, or “reduce smoking” as the search terms. One author abstracted data from included studies, and a second checked the abstracted data for accuracy.
The RCTs included met the following criteria: (a) had at least one comparison group (defined as placebo, no treatment, or minimal psychological interventions); (b) recruited adult smokers (age ≥ 18 years); (c) recruited only smokers who were not ready to make a quit attempt either immediately or in the next month; and (d) applied interventions to reduce the number of cigarettes smoked per day. We defined smokers unwilling to quit as those not ready to quit “either immediately or in the next month” to be consistent with the USPHS Clinical Practice Guideline’s (USPHS, 2008) definition of this group.
The primary outcome of interest was the 7-day point-prevalence smoking abstinence at the longest follow-up period, which had to be at least six months after randomization. The 6-month follow-up minimum was chosen to be consistent with published recommendations (Hughes, et al., 2003; Pierce & Gilpin, 2003).
Studies were grouped into three categories according to intervention type: pharmacological, behavioral, or combined (Table 1). We used odds ratios (ORs) to represent the point estimates of the magnitude of the association between intervention exposure and treatment outcomes such that an OR greater than one indicates that the odds of quitting were higher in the intervention group than in the control or comparison group. To represent the precision around this point estimate, 95% confidence intervals (CIs) were used. In studies in which the OR was not reported, we calculated it from abstinence rates by using cross-tabulation. We calculated the average weighted-effect size (OR) for each intervention group to accommodate for differences in sample size. To calculate the 95% CIs for the weighted ORs, we used the formula [100(1−α)% = OR**(1−z/sqrt(chi-square)], where z is the standard normal critical value (1.96 for α = .05, two-tailed) (Daniel, 2009). Specialized programs written in SAS/IML (Interactive Matrix Language) (bSAS Institute Inc, 2008b) were used to calculate the statistics, and SAS/Graph (Proc GANNO) was used to generate the forest plots (aSAS Institute Inc, 2008a).
Table 1
Table 1
Abstinence in studies testing pharmacological interventions, behavioral intervention, and combined (pharmacological and behavioral) interventions to reduce smoking rates among smokers not ready to quit.
Two studies had 3-arm designs (Carpenter, et al., 2004; Etter, Laszlo, & Perneger, 2004). The first such study (Carpenter, et al., 2004) had a control group (no intervention), a motivational intervention to quit plus nicotine replacement therapy (NRT) if participant decided to quit group, and a smoking reduction plus NRT group. For consistency, we analyzed the differences in quit rates between the combined smoking-reduction intervention and the control group. The second study (Etter, et al., 2004) also had a control group (no intervention), a placebo group, and an active NRT group. For consistency, we analyzed the differences between NRT and placebo. For these two studies, we used the sum of only the two comparison groups as a sample weight because of the possibility that including the third group would bias the weighted-effects’ size downward and increase the 95% CI. Heterogeneity was quantified by using the I2 statistic (Higgins, Thompson, Deeks, & Altman, 2003).
Six trials tested the efficacy of pharmacological interventions to reduce smoking rates (Table 1). Five trials examined NRT (Batra, et al., 2005; Bolliger, et al., 2000; Etter, et al., 2004; Rennard, et al., 2006; Wennike, Danielsson, Landfeldt, Westin, & Tonnesen, 2003); only one trial used bupropion(Hatsukami, et al., 2004). The pooled results of these trials show that the odds of abstinence from smoking are more than doubled by pharmacological interventions as compared with the odds under control conditions( 2732 participants; OR 2.33, 95% CI 1.43–3.79). Mild heterogeneity was suggested among the six trials (I2= 14.95%) (Fig 1).
Figure 1
Figure 1
Pharmacological (NRT and buproprion) rate reduction interventions vs placebo, and combined (pharmacological + behaviorial) rate reduction interventions vs usual care, point-prevalence abstinence at longest follow-up.
We identified only one trial examining the efficacy of behavioral intervention in reducing smoking rates (Glasgow, et al., 2009). The smoking abstinence rate favored the rate reduction group (6.7% vs. 4.4%) but was not significantly different than that in the control group (320 participants; OR 1.49, 95% CI 0.56 to 3.93) (Table 1).
We identified three studies examining the efficacy of combining behavioral and pharmacological interventions in reducing smoking rates (Carpenter, et al., 2003; Carpenter, et al., 2004; Joseph, et al., 2008) (Table 1). The average weighted-effects’ size for the intervention was significantly greater than the effect of the minimal care (638 participants; OR 2.14, 95% CI: 1.28–3.60). We did not find evidence of heterogeneity among these trials (I2 = 0%) (Fig 1).
Our results suggest that NRT and combined smoking-reduction interventions increase long-term cessation among smokers who are not ready to quit smoking. Insufficient evidence is available regarding the efficacy of behavioral smoking-reduction interventions in promoting future abstinence among this group.
Although it is encouraging that NRT alone may promote abstinence in smokers not ready to quit, a major barrier to implementing such protocols is the long duration of therapy given to participants in these studies, ranging from 6 (Etter, et al., 2004) to 18 months (Bolliger, et al., 2000). This may be a costly treatment plan given that the majority of patients receiving it will not quit smoking. The Clinical Practice Guidelines recommend that nicotine gum should be used for up to 12 weeks, nicotine inhalers for up to 6 months, and nicotine patches for 8 weeks to achieve optimal treatment for tobacco users interested in cessation (Fiore, et al., May 2008). Future studies should determine whether this treatment length is sufficient to produce a substantial treatment effect among smokers not ready to quit.
In the only study evaluating a behavioral smoking-reduction intervention (Glasgow, et al., 2009), the results favored the behavioral intervention but did not achieve statistical significance. The study’s authors attributed this to two factors: increased tobacco-control strategies during the study and high drop-out rates in the intervention group. Participants in this study were scheduled for either outpatient surgeries or diagnostic procedures which may have had a significant effect on their motivation before and after the medical procedure and on study retention. Future studies should evaluate smoking-reduction behavioral interventions in a general population of smokers not ready to quit and explore ways to enhance retention.
The three studies examining combined intervention methods showed a significant effect of smoking reduction aided by NRT. However, two of these studies observed negative results (Carpenter MJ, 2003; Joseph AM, 2008), which may have been due to small sample sizes. The remaining study (Carpenter, et al., 2004) observed a positive result. However, because the reduction intervention in this study consisted of two interventions (i.e., reduction counseling and the provision of free NRT), it is not clear whether the increase in quitting with NRT-assisted reduction is related to NRT availability, reduction itself, or both. Future studies should compare three groups: behavioral reduction intervention alone, NRT–assisted reduction with minimal behavioral support, and reduction intervention plus NRT to determine if behavioral counseling augments the effect of providing NRT.
An additional challenge in the literature is the lack of an operational definition of what constitutes a smoker who is “unwilling, unable, or not ready to quit smoking.” For the studies included in this review, the time frame for intention-to-quit varied from “not ready to quit in the next 6 months” to “not ready to quit immediately.” One possible approach would be to use the stages-of-change definitions of pre-contemplators and contemplators as a common definition for smokers who are “unwilling to quit” (Prochaska, Velicer, DiClemente, & Fava, 1988). A sample of contemplators may be more amenable to a rate-reduction intervention than pre-contemplators are. Another challenge is that most rate-reduction studies report only point-prevalence smoking abstinence. Future studies should follow the published recommendations for measuring abstinence (Hughes, et al., 2003) in trials of smokers not currently trying to quit by tying follow-up to the start of the intervention. An appropriate report would consist of prolonged abstinence as the primary outcome measure and point-prevalence abstinence as a secondary measure at 6-month follow-up.
In conclusion, pharmacological and combined smoking-reduction interventions double the odds of long-term smoking abstinence. Additional research is needed to further refine the behavioral interventions and the duration of pharmacotherapy that are most effective for smoking reduction.
Acknowledgments
Role of Funding Sources
This work was supported by the National Cancer Institute (CA127964) and by the National, Heart, Lung, and Blood Institute (HL053478) at the National Institutes of Health.
Footnotes
Contributors
Authors A, B, and C designed the study. Author A conducted literature searches, provided summaries of previous research studies, identified potentially eligible articles, and extracted data from these articles. Authors B and C contributed to the idea of the study, and participated in the planning of analysis and editing the manuscript. Author D checked the extracted data for accuracy and conducted the statistical analysis. Author A wrote the first draft of the manuscript and all authors contributed to and have approved the final manuscript.
Conflict of Interest
The author(s) declare that they have no conflicts of interest.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  • Batra A, Klingler K, Landfeldt B, Friederich HM, Westin A, Danielsson T. Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. Clinical Pharmacology and Therapeutics. 2005;78(6):689–696. [PubMed]
  • Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. British Medical Journal. 2000;321(7257):329–333. [PMC free article] [PubMed]
  • Burke BL, Arkowitz H, Menchola M. The efficacy of motivational interviewing: a meta-analysis of controlled clinical trials. Journal of Consulting and Clinical Psychology. 2003;71(5):843–861. [PubMed]
  • Carpenter MJ, Hughes JR, Keely JP. Effect of smoking reduction on later cessation: a pilot experimental study. Nicotine & Tobacco Research. 2003;5(2):155–162. [PubMed]
  • Carpenter MJ, Hughes JR, Solomon LJ, Callas PW. Both smoking reduction with nicotine replacement therapy and motivational advice increase future cessation among smokers unmotivated to quit. Journal of Consulting and Clinical Psychology. 2004;72(3):371–381. [PubMed]
  • CDC. Cigarette smoking among adults and trends in smoking cessation - United States, 2008. MMWR Morbidity and Mortality Weekly Report. 2009;58(44):1227–1232. [PubMed]
  • Cinciripini PM, Lapitsky L, Seay S, Wallfisch A, Kitchens K, Van Vunakis H. The effects of smoking schedules on cessation outcome: can we improve on common methods of gradual and abrupt nicotine withdrawal? Journal of Consulting and Clinical Psychology. 1995;63(3):388–399. [PubMed]
  • Daniel WW. Biostatistics: A foundation for Analysis in the Health Sciences. 9. New York: John Wiley & Sons; 2009.
  • Dunn C, Deroo L, Rivara FP. The use of brief interventions adapted from motivational interviewing across behavioral domains: a systematic review. Addiction. 2001;96(12):1725–1742. [PubMed]
  • Etter JF, Laszlo E, Perneger TV. Postintervention effect of nicotine replacement therapy on smoking reduction in smokers who are unwilling to quit: randomized trial. Journal of Clinical Psychopharmacology. 2004;24(2):174–179. [PubMed]
  • Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, U.S. Public Health Service; May, 2008.
  • Glasgow RE, Gaglio B, Estabrooks PA, Marcus AC, Ritzwoller DP, Smith TL, et al. Long-term results of a smoking reduction program. Medical Care. 2009;47(1):115–120. [PubMed]
  • Glasgow RE, Gaglio B, France EK, Marcus A, Riley KM, Levinson A, et al. Do behavioral smoking reduction approaches reach more or different smokers? Two studies; similar answers. Addictive Behaviors. 2006;31(3):509–518. [PubMed]
  • Glasgow RE, Morray K, Lichtenstein E. Controlled smoking versus abstinence as a treatment goal: The hopes and fears may be unfounded. [doi: DOI: 10.1016/S0005-7894(89)80119-4] Behavior Therapy. 1989;20(1):77–91.
  • Godtfredsen NS, Osler M, Vestbo J, Andersen I, Prescott E. Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976–1998: a pooled cohort study. Journal of Epidemiology and Community Health. 2003;57(6):412–416. [PMC free article] [PubMed]
  • Hatsukami DK, Hecht SS, Hennrikus DJ, Joseph AM, Pentel PR. Biomarkers of tobacco exposure or harm: application to clinical and epidemiological studies. 25–26 October 2001, Minneapolis, Minnesota. Nicotine & Tobacco Research. 2003;5(3):387–396. [PubMed]
  • Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA, et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. American Journal of Medicine. 2004;116(3):151–157. [PubMed]
  • Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal. 2003;327(7414):557–560. [PMC free article] [PubMed]
  • Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine & Tobacco Research. 2006;8(6):739–749. [PubMed]
  • Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine & Tobacco Research. 2003;5(1):13–25. [PubMed]
  • Joseph AM, Hecht SS, Murphy SE, Lando H, Carmella SG, Gross M, et al. Smoking reduction fails to improve clinical and biological markers of cardiac disease: a randomized controlled trial. Nicotine & Tobacco Research. 2008;10(3):471–481. [PubMed]
  • Kralikova E, Kozak JT, Rasmussen T, Gustavsson G, Le Houezec J. Smoking cessation or reduction with nicotine replacement therapy: a placebo-controlled double blind trial with nicotine gum and inhaler. Bio Med Central Public Health. 2009;9:433. [PMC free article] [PubMed]
  • Kunze M. Maximizing help for dissonant smokers. Addiction. 2000;95(Suppl 1):S13–17. [PubMed]
  • Lindson N, Aveyard P, Hughes JR. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev. 2010;3:CD008033. [PubMed]
  • Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. British Medical Journal. 2009;338:b1024. [PMC free article] [PubMed]
  • Pierce JP, Gilpin EA. A minimum 6-month prolonged abstinence should be required for evaluating smoking cessation trials. Nicotine & Tobacco Research. 2003;5(2):151–153. [PubMed]
  • Pisinger C, Godtfredsen NS. Is there a health benefit of reduced tobacco consumption? A systematic review. Nicotine & Tobacco Research. 2007;9(6):631–646. [PubMed]
  • Prochaska JO, Velicer WF, DiClemente CC, Fava J. Measuring processes of change: applications to the cessation of smoking. Journal of Consulting and Clinical Psychology. 1988;56(4):520–528. [PubMed]
  • Rennard SI, Glover ED, Leischow S, Daughton DM, Glover PN, Muramoto M, et al. Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. Nicotine & Tobacco Research. 2006;8(4):555–564. [PubMed]
  • Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. British Journal of General Practice. 2005;55(513):305–312. [PMC free article] [PubMed]
  • SAS Institute Inc. SAS/Graph User’s Guide, Version 9.2. Cary, NC: SAS Institute; 2008a.
  • SAS Institute Inc. SAS/IML User’s Guide, Version 9.2. Cary, NC: SAS Institute; 2008b.
  • Shiffman S, Gitchell JG, Warner KE, Slade J, Henningfield JE, Pinney JM. Tobacco harm reduction: conceptual structure and nomenclature for analysis and research. Nicotine & Tobacco Research. 2002;4(Suppl 2):S113–129. [PubMed]
  • Shiffman S, Hughes JR, Ferguson SG, Pillitteri JL, Gitchell JG, Burton SL. Smokers’ interest in using nicotine replacement to aid smoking reduction. Nicotine & Tobacco Research. 2007;9(11):1177–1182. [PubMed]
  • Stead LF, Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane Database of Systematic Reviews. 2007;(3):CD005231. [PubMed]
  • Tverdal A, Bjartveit K. Health consequences of reduced daily cigarette consumption. Tobacco Control. 2006;15(6):472–480. [PMC free article] [PubMed]
  • USDHHS. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease and Prevention and Health Promotion, Office on Smoking and Health; 2004.
  • USPHS. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respiratory Care. 2008;53(9):1217–1222. [PubMed]
  • Velicer WF, Fava JL, Prochaska JO, Abrams DB, Emmons KM, Pierce JP. Distribution of smokers by stage in three representative samples. Preventive Medicine. 1995;24(4):401–411. [PubMed]
  • Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D. ‘Cut down to quit’ with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. Health Technology Assessment. 2008;12(2):iii–iv. ix–xi, 1–135. [PubMed]
  • Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction. 2003;98(10):1395–1402. [PubMed]